Paclitaxel-based chemotherapy for aggressive kaposiform hemangioendothelioma of the temporomastoid region: Case report and review of the literature

Head Neck. 2013 Aug;35(8):E258-61. doi: 10.1002/hed.23107. Epub 2012 Aug 21.

Abstract

Background: Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor of infancy and childhood. This tumor results in poor prognosis, and therefore, development of a more effective treatment is needed.

Methods and results: We describe an 11-year-old boy presenting with left facial palsy caused by aggressive KHE of the left temporomastoid region. He was treated with paclitaxel-based chemotherapy, because of the difficulty with complete surgical resection for anatomic factor, multiple lung metastases on diagnosis, and no response to conventional treatments. This treatment reduced the volume of primary tumor and lung metastatic lesions, but the efficacy was transitory.

Conclusions: Paclitaxel-based chemotherapy for aggressive KHE may be effective, therefore the multimodality therapy including paclitaxel of aggressive KHE, particularly in the head and neck, needs to be investigated in further studies.

Keywords: Kaposiform hemangioendothelioma; angiosarcoma; chemotherapy; head and neck; paclitaxel.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Antineoplastic Agents, Phytogenic / therapeutic use*
  • Child
  • Head and Neck Neoplasms / pathology
  • Head and Neck Neoplasms / therapy*
  • Hemangioendothelioma / secondary*
  • Hemangioendothelioma / therapy*
  • Humans
  • Kasabach-Merritt Syndrome / secondary*
  • Kasabach-Merritt Syndrome / therapy*
  • Lung Neoplasms / secondary
  • Lung Neoplasms / therapy*
  • Male
  • Paclitaxel / therapeutic use*
  • Sarcoma, Kaposi / secondary*
  • Sarcoma, Kaposi / therapy*

Substances

  • Antineoplastic Agents, Phytogenic
  • Paclitaxel

Supplementary concepts

  • Kaposiform Hemangioendothelioma